Assessing Novavax (NVAX) Valuation As Shah Capital Challenges Leadership And Sanofi Partnership

Activist pressure puts Novavax (NVAX) leadership under scrutiny

Shah Capital Management has challenged Novavax (NVAX) leadership in a detailed Elevating Novavax Presentation, criticizing marketing since 2023, the Sanofi partnership, capital market decisions, and executive conduct toward shareholder value.

See our latest analysis for Novavax.

The activist presentation lands after a period where momentum in Novavax’s share price has been mixed, with a 1-month share price return of 8.99% and a year-to-date share price return of 29.17%, set against a 1-year total shareholder return of 27.03% and a 5-year total shareholder return that has declined 93.76%.

If activism at Novavax has you reassessing opportunities in healthcare, this can be a useful moment to scan other vaccine and drug developers using our healthcare AI stock screener, starting with 34 healthcare AI stocks.

With Novavax shares up 29.17% year to date, but the stock still trading at a discount to analyst price targets and intrinsic estimates, investors now face a key question: is there genuine value left, or is potential future growth already reflected in the current price?

Most Popular Narrative: 33.2% Undervalued

With Novavax last closing at $9.21 against a narrative fair value of $13.78, the current pricing sits below what this widely followed framework suggests.

The global vaccine market is expected to increase significantly, driven by factors such as aging populations and emerging infectious diseases, expanding Novavax's addressable market and supporting long-term revenue growth. Partnership with Sanofi has de-risked commercial execution for Nuvaxovid and opened doors for future milestone and royalty streams, particularly as Sanofi develops and commercializes COVID influenza combination vaccines, which could meaningfully boost Novavax's recurring revenue and net margins.

Read the complete narrative.

Curious what sits behind that valuation gap? The narrative leans heavily on shifting revenue mix, higher margin licensing income, and a future earnings multiple more often reserved for sector standouts.

Result: Fair Value of $13.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on partners like Sanofi and Pfizer delivering on milestones, as well as COVID vaccine demand not falling away faster than analysts currently model.

Find out about the key risks to this Novavax narrative.

Another View: Market Ratios Flash A Different Signal

While the SWS DCF model points to NVAX as undervalued, the P/S ratio sends a cooler message. At 2.5x sales versus a fair ratio of 1.6x, the stock trades well above where the ratio could move. This raises the question of how much downside investors are willing to tolerate if sentiment turns.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and sentiment, it makes sense to review the numbers yourself and decide how much risk and reward you are comfortable with, starting with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on fresh opportunities that better match your goals, time horizon, and comfort with risk.

• Target resilient potential by reviewing companies that score well on financial strength and fundamentals with the solid balance sheet and fundamentals stocks screener (46 results).
• Spot underappreciated opportunities early by scanning the screener containing 21 high quality undiscovered gems before they sit on everyone else's radar.
• Focus on quality at a sensible price by checking companies highlighted as 49 high quality undervalued stocks, so you do not overlook ideas that might fit your checklist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com